Education
About Us
Working with TipRanks
Follow Us
Opko Health Inc (OPK)
NASDAQ:OPK
Top Page
Opko Health
(NASDAQ:OPK)
Select Model
Select Model
Rating:50Neutral
Price Target:
$1.50
▼(-1.96% Downside)
Opko Health's overall stock score reflects significant financial challenges, with declining revenues and profitability issues being the most impactful factors. The strategic initiatives and partnerships highlighted in the earnings call provide some optimism, but technical and valuation metrics remain weak.
Opko Health (OPK) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.02B
Dividend YieldN/A
Average Volume (3M)2.18M
Price to Earnings (P/E)―
Beta (1Y)0.74
Revenue Growth-9.75%
EPS Growth-31.28%
CountryUS
Employees2,997
SectorN/A
Sector StrengthN/A
IndustryMedical - Diagnostics & Research
Share Statistics
EPS (TTM)0.03
Shares Outstanding767,701,300
10 Day Avg. Volume1,466,492
30 Day Avg. Volume2,176,778
Financial Highlights & Ratios
PEG Ratio0.28
Price to Book (P/B)0.75
Price to Sales (P/S)1.43
P/FCF Ratio-4.89
Enterprise Value/Market Cap1.15
Enterprise Value/Revenue1.83
Enterprise Value/Gross Profit4.75
Enterprise Value/Ebitda26.10
Forecast
1Y Price Target
$2.75Price Target Upside79.74% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Opko Health Business Overview & Revenue Model
Company DescriptionOpko Health, Inc. is a diversified healthcare company focused on developing and commercializing innovative health solutions. The company operates primarily in the pharmaceuticals and diagnostics sectors, offering a range of products including proprietary pharmaceuticals, diagnostic products, and novel drug delivery systems. Opko Health is known for its commitment to advancing medical technology and improving patient outcomes through its core products such as the 4Kscore Test, a diagnostic test for prostate cancer, and a portfolio of pharmaceutical products that address various medical needs.
How the Company Makes MoneyOpko Health generates revenue through multiple streams, primarily from the sale of pharmaceuticals and diagnostic tests. The company markets its proprietary drugs and therapies, including treatments for endocrinology and urology. Additionally, Opko's 4Kscore Test contributes significantly to its revenue, being a leading diagnostic tool for prostate cancer detection. The company also engages in partnerships and collaborations with other healthcare organizations, which can result in shared revenue from co-developed products or licensing agreements. Furthermore, Opko has a focus on research and development, which may lead to new product offerings and additional revenue streams in the future.
Opko Health Earnings Call Summary
Earnings Call Date:Oct 29, 2025
(Q3-2025)
| % Change Since: |
Next Earnings Date:Feb 19, 2026
Earnings Call Sentiment Positive
The earnings call reflects strong strategic moves such as the sale of non-core assets and significant partnerships, contributing to financial improvements and shareholder value. However, there are challenges in diagnostics revenue decline and slower-than-expected market conversion affecting Pfizer profit share.Q3-2025 Updates
Positive Updates
Sale of BioReference Health's Oncology Division
Completed the sale of BioReference Health's oncology division, providing $192.5 million at closing and $32.5 million in performance-based earn-out, streamlining lab business for profitable growth.
Significant Partnerships for Therapeutics
Announced a research collaboration and license agreement with Regeneron, with milestone payments potentially totaling over $1 billion, and continued partnership with Merck on EBV vaccine development.
Stock Repurchase Program
Repurchased $25.1 million worth of stock in 2025, with $126 million remaining under the program, demonstrating commitment to increasing shareholder value.
4Kscore Test Growth
4Kscore test volume increased more than 20% in the third quarter compared to the previous year, with FDA label expansion opening new markets.
Improved Financial Performance
Consolidated operating income improved to $48.1 million from $14.2 million in 2024, driven by improved results at BioReference.
Negative Updates
Decline in Diagnostics Revenue
Q3 2025 diagnostics revenue was $95.2 million, down from $121.3 million in Q3 2024, primarily due to the sale of oncology assets.
Foreign Currency Headwinds
Lower sales in Chile and foreign currency pressures affected pharmaceutical revenues.
Challenges with Pfizer Profit Share
Slow market conversion to weekly regimen affecting Pfizer profit share, with a forecasted increase of only 10% to 15% for 2026.
Company Guidance
During the OPKO Health Third Quarter 2025 Financial Results Conference Call, the company provided guidance on several key metrics and strategic initiatives. OPKO Health completed the sale of BioReference Health's oncology division, yielding $192.5 million at closing and a potential $32.5 million in performance-based earn-out, which will be used in part for a stock repurchase program with $126 million remaining for repurchases. The company reported a 20% increase in the 4Kscore test volume, with expected revenue growth due to a recent FDA label expansion. The pharmaceutical segment is advancing with four candidates in clinical trials and several in pre-IND stages, supported by partnerships providing nondilutive funding. A significant collaboration was announced with Regeneron to leverage ModeX's MSTAR platform for developing multispecific antibodies, with potential milestone payments exceeding $1 billion. Financially, OPKO ended the third quarter with $428 million in cash and cash equivalents and repurchased nearly 25 million shares for approximately $33.5 million this year. The company projected a Q4 2025 revenue range of $135-$140 million and outlined a 2026 outlook anticipating low single-digit revenue growth in diagnostics and mid-single-digit growth in pharmaceuticals, with a focus on profitability and strategic capital allocation to enhance shareholder value.Opko Health Financial Statement Overview
Summary
Income Statement
45
Neutral
Balance Sheet
55
Neutral
Cash Flow
40
Negative
| Breakdown |
|---|
Income Statement |
| Total Revenue |
| Gross Profit |
| EBITDA |
| Net Income |
Balance Sheet |
| Total Assets |
| Cash, Cash Equivalents and Short-Term Investments |
| Total Debt |
| Total Liabilities |
| Stockholders Equity |
Cash Flow |
| Free Cash Flow |
| Operating Cash Flow |
| Investing Cash Flow |
| Financing Cash Flow |
Opko Health Technical Analysis
Negative
1.53
Price Trends
1.38
Negative
1.39
Negative
1.41
Negative
Market Momentum
-0.01
Positive
47.09
Neutral
21.56
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For OPK, the sentiment is Negative. The current price of 1.53 is above the 20-day moving average (MA) of 1.34, above the 50-day MA of 1.38, and above the 200-day MA of 1.41, indicating a bearish trend. The MACD of -0.01 indicates Positive momentum. The RSI at 47.09 is Neutral, neither overbought nor oversold. The STOCH value of 21.56 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for OPK.
Opko Health Peers Comparison
UnderperformOutperform
Sector (―)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| ― | ― | ― | ― | ― | ― | ― | |
77 Outperform | $1.03B | 16.79 | 24.11% | ― | 14.46% | ― | |
63 Neutral | $1.21B | -89.31 | -2.69% | ― | 10.15% | -295.52% | |
57 Neutral | $854.42M | -19.38 | -3.80% | ― | 13.60% | 74.64% | |
55 Neutral | $1.61B | -13.99 | -12.99% | ― | 10.10% | -44.29% | |
50 Neutral | $1.02B | -5.31 | -13.32% | ― | -9.75% | -31.28% | |
41 Neutral | $630.12M | -1.51 | -72.52% | ― | 0.21% | -233.51% |
* Sector Average
OPK
Opko Health
1.31
-0.20
-13.25%
MYGN
Myriad Genetics
6.56
-7.18
-52.26%
NEO
NeoGenomics
12.42
-4.73
-27.58%
CDNA
CareDx
20.02
-1.40
-6.54%
FLGT
Fulgent Genetics
27.16
8.65
46.73%
CSTL
Castle Biosciences
40.20
12.48
45.02%
Opko Health Corporate Events
M&A TransactionsBusiness Operations and Strategy
Opko Health Sells BioReference Assets to Labcorp
Positive
Sep 15, 2025
On September 15, 2025, OPKO Health, Inc. completed the sale of certain assets of its subsidiary, BioReference Health, to Laboratory Corporation of America Holdings (Labcorp) for up to $225 million. This transaction, which includes BioReference’s oncology and clinical testing services, marks a strategic shift for OPKO, allowing it to focus on core clinical testing operations and the growth of its 4Kscore Test franchise, while Labcorp expands its oncology services portfolio.
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.